Cyfuse Biomedical K.K.

4892

TSE PrimePharmaceuticals

¥ -

You can review earnings summary, quarterly trends, full-year progress, and detailed income statement data.

descriptionIncome Statement (PL) Summary

Updated: 2026-08-14FY2026 Q2

Revenue

3.1100M JPY

YoY +364.7%

Operating Income

-4.2100M JPY

YoY +11.4%

Net Income

-8100M JPY

YoY +3.8%

EPS

-43.5JPY

YoY +11.1%

Performance Trend

Revenue, operating income and net income trend (last 5 periods)

RevenueOperatingNet Income

3.7億円

56.8百万円

-2.6億円

-5.8億円

-9億円

Rev: 3.7億円Op: -4.3億円NI: -4.7億円

Rev: 61.1百万円Op: -7億円NI: -5.9億円

Rev: 54.4百万円Op: -9億円NI: -8.7億円

Rev: 2.3億円Op: -8.3億円NI: -7.6億円

2022/FY2023/FY2024/FY2025/FY

Full-Year Progress

FY2026 Q2

Net Income-

Revenue Progress100M

Revenue Forecast2.800M

Net Income Progress-

Net Income Forecast-

Income Statement Details

Unit: JPY

Unlock Long-Term Financial Data

Your current plan allows viewing financial data for the latest 1 year (annual only). Upgrade to the Standard Plan to view up to 3 years (including quarterly data), or the Premium Plan to access all historical data.

Standard Plan Premium Plan